Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update at the Jefferies London Healthcare Conference via a virtual presentation, which will be available to view on the conference website on November 18-19, 2021.

The recorded audio presentation will be available within the Investors & Media section of the Rubius Therapeutics website on November 18^th beginning at 8:00 a.m. ET. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, VP Investor Relations
[email protected]

Media
Marissa Hanify, Director, Corporate Communications
[email protected]

You May Also Be Interested In

• K Wave Media Ltd. Announces Pricing of $1.0 Million Registered Direct Offering
• NetworkNewsBreaks – HWAL, Inc. (OTCID: HWAL) Joint Venture Lunar Records to Support Media Coverage for Global Passion Projects Legacy Events
• The Digital Imaging Channel Tops 700 Subscribers on YouTube